SLGL | tickerfilter.com

Fundamental analysis

21%

Profitability 25%

Dept financing 9%

Liquidity 43%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.29%

1 Month

-9.64%

3 Months

26.09%

6 Months

85.38%

1 Year

9,217.01%

2 Year

7,758.70%

Key data

Stock price

$72.30

P/E Ratio

0.00

DAY RANGE

$69.90 - $73.10

EPS

-$1.44

52 WEEK RANGE

$0.62 - $97.97

52 WEEK CHANGE

$9,143.16

MARKET CAP

19.470 M

YIELD

N/A

SHARES OUTSTANDING

27.858 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-29-2025

BETA

2.82

PUBLIC FLOAT

AVERAGE 10 VOLUME

$43,401

AVERAGE 30 VOLUME

$64,932

Company detail

CEO: Alon Seri-Levy
Region: US
Website: sol-gel.com
Employees: 50
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sol-Gel Technologies Ltd. focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system. Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris, Epsolay, SGT-210, and Erlotinib, Tapinarof, and roflumilast are the company's lead product candidates.

SLGL - Sol-Gel Technologies Ltd.